Reservoir Neuroscience
Overview
Reservoir Neuroscience is a biotechnology company founded in 2019, based in Emeryville, California. It specializes in developing therapeutics to repair dysfunctional blood vessels in the brain, focusing on treatments for neurological diseases such as Alzheimer's and epilepsy. Co-founded by neuroscientists Aaron Friedman and Vlad Senatorov from UC Berkeley, the company has secured approximately $5.96 million in funding. Reservoir Neuroscience harnesses innovative technology to address neurodegenerative diseases by restoring the integrity of the brain's blood vessels.
Recent Developments
Reservoir Neuroscience has been actively pursuing collaborations and funding to advance its therapeutic developments:
- March 2025: In a collaboration with SynapCell, Reservoir Neuroscience is developing treatments for drug-resistant Mesio-Temporal Lobe Epilepsy. Utilizing SynapCell's translational epilepsy model, the partnership aims to identify promising drug candidates for clinical trials.
- January 2024: Reservoir Neuroscience secured $4 million in a funding round led by Kizoo Technology Capital. The funding is earmarked for developing therapies aimed at rejuvenating aging brains by repairing blood vessels, and it supports Reservoir’s novel class of drug compounds.
- December 2023: The company emphasized the potential systemic benefits of its therapies for various aging-related diseases, highlighting its strategy to target vascular decline as a precursor to neurodegeneration.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2019 |
| Headquarters | Emeryville, California, USA |
| Founders | Aaron Friedman, Vlad Senatorov |
| Key Investors | Kizoo Technology Capital, R42 Fund |
| Industry | Biotechnology, Drug Discovery |
| Number of Employees | Less than 10 |
| Funding Raised | Approximately $5.96 million |
Early History
Reservoir Neuroscience was established in 2019 by Aaron Friedman and Vlad Senatorov, who were motivated by their research at UC Berkeley into how aging affects blood vessels in the brain. The company initially focused on understanding and targeting the blood-brain barrier as a novel therapeutic avenue. Using advanced organ-on-chip technology, Reservoir developed unique compounds aiming to restore the health of these blood vessels, thereby addressing the root causes of neurological diseases like Alzheimer's.
Company Profile and Achievements
Reservoir Neuroscience employs a business model centered around innovation within the therapeutic landscape for neurodegenerative diseases. Its organ-on-chip platform allows for the modeling of human blood vessels to study vascular pathology and aging.
- Innovative Therapeutics: Developed first-in-kind drug candidates addressing vascular damage and permeability issues in the brain's blood vessels.
- Collaborative Partnerships: Engaged in key collaborations for drug development, such as with SynapCell for evaluating epilepsy treatments.
- Strategic Funding: Successfully attracted investment from notable sources focused on rejuvenation and aging-related biotech ventures, enabling sustained R&D efforts.
- Research Recognition: Garnered attention from the scientific community for its potential in addressing aging and neurodegenerative conditions through vascular health.
Current Operations and Market Position
Reservoir Neuroscience is at the forefront of innovative drug development with its focus on vascular health as a foundational factor in neurodegenerative diseases. The company competes within the biotechnology sector, offering a unique approach by targeting the blood-brain barrier’s integrity, which positions it uniquely in the market. Reservoir's strategic focus on age-related vascular decline also stands out as a differentiation factor in its treatment methodologies, potentially influencing broader therapeutic strategies across the industry.
Conclusion
Reservoir Neuroscience holds a significant position in the biotech sector with its pioneering approach to neurodegenerative diseases through vascular health. By focusing on the blood-brain barrier’s role in age-related pathologies, the company not only addresses a crucial aspect of neurodegeneration but also opens up possibilities for more targeted and effective therapies. As it continues to innovate and expand its therapeutic pipeline, Reservoir Neuroscience could play a transformative role in the treatment of brain-related diseases, significantly impacting both the biotech industry and patient care strategies in the years to come.